Exagen Inc. (NASDAQ:XGN) Short Interest Update

Exagen Inc. (NASDAQ:XGN) saw a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 11,900 shares, a decline of 42.0% from the March 31st total of 20,500 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily volume of 38,200 shares, the short-interest ratio is currently 0.3 days.

Exagen Stock Performance

Shares of XGN stock opened at $1.40 on Friday. The stock has a market capitalization of $24.14 million, a price-to-earnings ratio of -1.04 and a beta of 1.19. Exagen has a one year low of $1.30 and a one year high of $3.92. The company’s 50-day simple moving average is $1.69 and its 200-day simple moving average is $1.77. The company has a debt-to-equity ratio of 0.85, a quick ratio of 4.02 and a current ratio of 4.02.

Exagen (NASDAQ:XGN) last released its earnings results on Monday, March 18th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.02). Exagen had a negative return on equity of 80.28% and a negative net margin of 45.08%. The firm had revenue of $13.77 million for the quarter, compared to the consensus estimate of $11.43 million. During the same period in the prior year, the business earned ($0.58) EPS. Equities analysts anticipate that Exagen will post -1.46 earnings per share for the current fiscal year.

Institutional Trading of Exagen

Institutional investors have recently added to or reduced their stakes in the business. Perkins Capital Management Inc. grew its holdings in shares of Exagen by 92.8% during the fourth quarter. Perkins Capital Management Inc. now owns 508,905 shares of the company’s stock valued at $1,013,000 after purchasing an additional 245,000 shares during the last quarter. Stonepine Capital Management LLC boosted its position in Exagen by 14.7% during the 3rd quarter. Stonepine Capital Management LLC now owns 1,203,491 shares of the company’s stock valued at $2,912,000 after purchasing an additional 154,139 shares during the period. Finally, RTW Investments LP grew its stake in Exagen by 0.8% during the 4th quarter. RTW Investments LP now owns 1,504,602 shares of the company’s stock worth $2,994,000 after buying an additional 12,170 shares during the last quarter. Institutional investors own 75.25% of the company’s stock.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).